Breast cancer: initial workup and staging with FDG PET/CT.
David Groheux,Elif Hindié +1 more
Reads0
Chats0
TLDR
In this paper, the authors performed a comprehensive literature review and rigorous appraisal of research studies assessing indications for FDG-PET/CT in breast cancer, concluding that FDG PET/CT is useful for staging patients with breast cancer starting from clinical stage IIB.Abstract:
Precise staging is needed to plan optimal management in breast cancer. 18F-fluorodeoxyglucose positron emission tomography coupled with computed tomography (FDG-PET/CT) offers high sensitivity in detecting extra axillary lymph nodes and distant metastases. This review aims to clarify in which groups of patients staging with FDG-PET/CT would be beneficial and should be offered. We also discuss how tumor biology and breast cancer subtypes should be taken into account when interpreting FDG-PET/CT scans. We performed a comprehensive literature review and rigorous appraisal of research studies assessing indications for FDG-PET/CT in breast cancer. This assessment regarding breast cancer served as a basis for the recommendations set by a working group of the French Society of Nuclear Medicine, in collaboration with oncological societies, for developing good clinical practice recommendations on the use of FDG-PET/CT in oncology. FDG-PET/CT is useful for initial staging of breast cancer, independently of tumor phenotype (triple negative, luminal or HER2 +) and regardless of tumor grade. Considering histological subtype, FDG-PET/CT performs better for staging invasive ductal carcinoma, although it is also helpful for staging invasive lobular carcinomas. Based on the available data, FDG-PET/CT becomes useful for staging starting from clinical stage IIB. FDG-PET/CT is possibly useful in patients with clinical stage IIA (T1N1 or T2N0), but there is not enough strong data to recommend routine use in this subgroup. For clinical stage I (T1N0) patients, staging with FDG-PET/CT offers no added value. FDG-PET/CT is useful for staging patients with breast cancer, starting from clinical stage IIB.read more
Citations
More filters
Journal ArticleDOI
Clinical advances in PET-MRI for breast cancer.
Amy M. Fowler,Roberta M. Strigel +1 more
TL;DR: A review of the clinical evidence for the use of PET-MRI in diagnosis, staging, prognosis, tumour phenotyping, and assessment of treatment response in breast cancer is presented in this paper .
Journal ArticleDOI
Radionuclide-Based Imaging of Breast Cancer: State of the Art
TL;DR: The rapid development of radionuclide probes aids the diagnosis of breast cancer in various aspects as discussed by the authors, such as target metabolism, amino acid transporters, cell proliferation, hypoxia, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), gastrin-releasing peptide receptor (GRPR) and so on.
Journal ArticleDOI
Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer
Mohammad Naghavi-Behzad,Hjalte Rasmus Oltmann,Tural Asgharzadeh Alamdari,Jakob Lykke Bülow,Lasse Ljungstrøm,Poul-Erik Braad,Poul-Erik Braad,Jon Thor Asmussen,Marianne Vogsen,Annette R Kodahl,Annette R Kodahl,Oke Gerke,Oke Gerke,Malene Hildebrandt +13 more
TL;DR: In this article, the authors compared response categories and impacts on treatment decisions for metastatic breast cancer patients that are response-monitored with contrastenhanced computed-tomography (CE-CT) or fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT).
Journal ArticleDOI
Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors
Clément Morgat,Véronique Brouste,Adrien Chastel,Valérie Vélasco,Gaëtan MacGrogan,Elif Hindié,Elif Hindié +6 more
TL;DR: In this paper, the authors used the Tissue Microarray (TMA) of primary breast tumors from Institut Bergonie to study the association between NTS1 expression and clinical, pathological, and biological parameters, as well as patient outcomes.
Journal ArticleDOI
Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer.
Umut Elboga,Ertan Sahin,Tulay Kus,Yusuf Burak Çayırlı,Gokmen Aktas,Evren Uzun,Havva Yesil Cinkir,Fatih Teker,Özlem Nuray Sever,Alper Aytekin,Latif Yilmaz,Aydin Aytekin,Ufuk Cimen,Vuslat Mumcu,Benan Kilbas,Y. Zeki Çelen +15 more
TL;DR: In this paper, the authors compared the ability of 68Ga-FAPI PET/CT with 18FDG PET-CT imaging techniques to detect additional lesions in breast cancer patients that may affect further chemotherapy options.
References
More filters
Journal ArticleDOI
Cancer Statistics, 2021.
TL;DR: In the United States, the cancer death rate has dropped continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment as mentioned in this paper.
Journal ArticleDOI
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
TL;DR: A marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping are notable.
Journal ArticleDOI
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Mustafa A. Arain,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Linda Farkas,Ignacio Garrido-Laguna,Jean L. Grem,Andrew J. Gunn,J. Randolph Hecht,Sarah E. Hoffe,Joleen M. Hubbard,Steven C. Hunt,Kimberly L. Johung,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,Steven J. Nurkin,Michael J. Overman,Aparna Raj Parikh,Hitendra Patel,Katrina S. Pedersen,Leonard B. Saltz,Charles Schneider,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Kristina M. Gregory,Lisa A. Gurski +38 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section as discussed by the authors.
Journal ArticleDOI
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Armando E. Giuliano,James L. Connolly,Stephen B. Edge,Elizabeth A. Mittendorf,Hope S. Rugo,Lawrence J. Solin,Donald L. Weaver,David J. Winchester,Gabriel N. Hortobagyi +8 more
TL;DR: The American Joint Commission of Cancer (AJCC) published the 8th edition of the primary tumor, lymph node, and metastasis (TNM) classification for breast cancer as discussed by the authors.
Journal ArticleDOI
Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography
Reinhard Bos,Jacobus J.M. van der Hoeven,Elsken van der Wall,Petra van der Groep,Paulus Joannes van Diest,Emile F.I. Comans,Urvi Joshi,Gregg L. Semenza,Otto Hoekstra,Adriaan A. Lammertsma,Carla F. M. Molthoff +10 more
TL;DR: Variable uptake of the glucose analog 18fluorodeoxyglucose (FDG) has been noticed in positron emission tomography (PET) studies of breast cancer patients, with low uptake occurring especia.